Oct 11, 2024 · Ojjaara (momelotinib) may be used to treat adults with certain types of myelofibrosis (MF) who have anemia. It is a targeted treatment that belongs to the drug class called Janus Kinase inhibitors.

OJJAARA is the first and only FDA-approved treatment specifically for adults with certain types of myelofibrosis (MF) who have anemia. It is not known if OJJAARA is safe and effective in children.

Aug 10, 2024 · Ojjaara is a JAK inhibitor that works to target JAKs in the bone marrow. Ojjaara also works to increase the number of red blood cells in the body by inhibiting a protein called activin A...

Discover OJJAARA (momelotinib), a treatment option for patients who have myelofibrosis (MF) with anemia. See full indication, safety, & prescribing information.

Sep 15, 2023 · GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved Ojjaara (momelotinib) for the treatment of intermediate or high-risk myelofibrosis, including primary myelofibrosis or secondary myelofibrosis (post-polycythemia vera and post-essential thrombocythemia), in adults with anemia.

Momelotinib, sold under the brand name Ojjaara among others, is an anticancer medication used for the treatment of myelofibrosis. [5] It is a Janus kinase inhibitor and it is taken by mouth.

Sep 19, 2023 · OJJAARA is indicated for the treatment of intermediate or high-risk myelofibrosis (MF), including primary MF or secondary MF [post-polycythemia vera (PV) and post-essential thrombocythemia (ET)], in adults with anemia. The recommended dosage of OJJAARA is 200 mg orally once daily. OJJAARA may be taken with or without food.

Sep 15, 2023 · Ojjaara is a once-a-day, oral JAK1/JAK2 and activin A receptor type 1 (ACVR1) inhibitor. To date, it is the only approved medicine for both newly diagnosed and previously treated myelofibrosis patients with anaemia that addresses the key manifestations of the disease, namely anaemia, constitutional symptoms, and splenomegaly (enlarged spleen).

Sep 15, 2023 · OJJAARA is indicated for the treatment of intermediate or high-risk myelofibrosis (MF), including primary MF or secondary MF [post-polycythemia vera (PV) and post-essential thrombocythemia (ET)] ...

OJJAARA is the first and only FDA-approved treatment specifically for adults with certain types of myelofibrosis (MF) who have anemia. It is not known if OJJAARA is safe and efective in children.